RESUMO
Interleukin-3 (IL-3) regulates the proliferation, survival and differentiation of haematopoietic cells via interaction with specific cell-surface receptors. IL-3 is expressed in several non-hematopoietic cell types. Studies have demonstrated the presence of IL-3 in the central nervous system, however, its physiological role in these cells is poorly understood. Previously we have been demonstrated that IL-3 prevents neuronal death induced by fibrillary ß amyloid in these cells, by PI 3-kinase and Jak/STAT pathway activation. In this study, we demonstrated that IL-3 significantly reduced Aß-promoted neurite degeneration and toxicity. Thus, this cytokine provides cellular protection against Aß neurotoxicity in primary cortical neuronal cells, by modulating microtubular dynamics and prevention of tau cleavage and hyperphosphorylation. We also demonstrates that IL-3 is expressed in the "in vivo" mouse model of AD, Tg2576, which also expresses human AßPP with the Swedish mutation. In summary, these results suggest that IL-3 could play a neuroprotective role in AD.
Assuntos
Doença de Alzheimer/metabolismo , Citoproteção/fisiologia , Interleucina-3/fisiologia , Degeneração Neural/metabolismo , Degeneração Neural/prevenção & controle , Proteínas tau/metabolismo , Doença de Alzheimer/tratamento farmacológico , Doença de Alzheimer/patologia , Peptídeos beta-Amiloides/antagonistas & inibidores , Peptídeos beta-Amiloides/toxicidade , Animais , Células Cultivadas , Citoproteção/efeitos dos fármacos , Humanos , Interleucina-3/uso terapêutico , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Degeneração Neural/patologia , Proteínas tau/fisiologiaRESUMO
Nosotros hemos tratado 2 pacientes con interleucina-3, uno de ellos con sindrome mielodisplasico y el otro con Aplasia Medular Severa. El propósito del tratamiento fue incrementar el número de plaquetas y observar la variación de las células sanguineas periféricas. Ambos pacientes mostraron una elevación transitoria del número de plaquetas no habiendo alteraciones de las otras series sanguineas. La dosis utilizada fue de 10ug/Kg de peso por inyección subcutanea diaria, presentando ambos pacientes purpura, fiebre y mialgias generalizadas. Nosotros concluimos que la IL-3 podría ser de utilidad en aumentar el número de plaquetas en pacientes que tienen falla medular, sin embargo es necesario incluir más pacientes para determinar el verdadero rol de esta citoquina en este tipo de enfermedades
Assuntos
Adulto , Interleucina-3/efeitos adversos , Interleucina-3/uso terapêutico , Fatores de Crescimento de Células HematopoéticasRESUMO
Repetitive administration of recombinant IL-3 induced protection against Strongyloides ratti but not against Nippostrongylus brasiliensis in C57BL/6 mice. Numbers of S. ratti were negligible from day 4 to day 6 post-infection in mice injected with IL-3, whereas N. brasiliensis burdens were almost equal from day 4 to day 6 between mice injected with IL-3 or with medium. Mice treated with IL-3 and then concurrently infected with S. ratti and N. brasiliensis were protected from intestinal S. ratti but not from N. brasiliensis. The numbers of intestinal mucosal mast cells were increased by the repetitive IL-3 treatment on one day after the final injection and was augmented by subsequent infection with both nematodes.